Efficacy, Safety, and Tolerability of Fosmetpantotenate (RE-024), A Phosphopantothenate Replacement Therapy, in Pantothenate Kinase-Associated Neurodegeneration (PKAN) Patients: A Randomized, Double Blind, Placebo Controlled Study With an Open Label Extension

Trial Profile

Efficacy, Safety, and Tolerability of Fosmetpantotenate (RE-024), A Phosphopantothenate Replacement Therapy, in Pantothenate Kinase-Associated Neurodegeneration (PKAN) Patients: A Randomized, Double Blind, Placebo Controlled Study With an Open Label Extension

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Dec 2017

At a glance

  • Drugs Fosmetpantotenate (Primary)
  • Indications Pantothenate kinase-associated neurodegeneration
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms FORT
  • Sponsors Retrophin
  • Most Recent Events

    • 07 Nov 2017 According to a Retrophin, Inc. media release, this trial is on track to complete patient enrolment in the second half of 2018.
    • 08 Sep 2017 Planned End Date changed from 1 Dec 2020 to 1 Jul 2022.
    • 08 Sep 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Jul 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top